A Phase II study of topotecan in patients with recurrent head and neck cancer: Identification of an active new agent

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 3, 1997, Pages 298-302

  Robert, Francisco ^a,b   Soong, Seng Jaw ^a   Wheeler, Richard H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Chemotherapy; Head and neck cancer; Topotecan

Indexed keywords

GYRASE INHIBITOR; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RECURRENT CANCER; VOMITING;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPENIA; QUALITY OF LIFE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TOPOTECAN;

EID: 0030941343     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199706000-00019     Document Type: Article

References (22)

1. Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomized factorial phase III controlled trial. Cancer Chemother Pharmacol 1985;15:283-9.
2. Wheeler RH. Chemotherapy of patients with recurrent head and neck cancers. In: Jacobs C, ed. Carcinomas of the head and neck: evaluation, management. Boston: Kluwer Academic, 1990:171-93.
3. Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 1983;52:206-10.
4. Tapazoglou E, Kish J, Ensley J, et al. The activity of a single agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer. Cancer 1986;51:1105-9.
5. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
6. Forastiere AA, Neuberg D, Leong T, et al. Eastern Cooperative Oncology Group (ECOG) paclitaxel studies in advanced head and neck cancer [Abstract]. Head Neck 1994;16:481.
7. Dreyfuss A, Clark J, Norris R, et al. Taxolere: a promising new drug for squamous cell carcinoma of the head and neck [Abstract]. Head Neck 1994;16:481.
8. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.
9. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989;989:163-77.
10. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase-I DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.
11. Husain I, Mohler JL, Seigler HF, et al. Elevation of topoisomerase 1 messenger RNA, protein and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994;54:539-46.
12. Johnson RK, McCabe FL, Faucette LF, et al. SK and F104864, a water soluble analog of camptothecin with a broad spectrum activity in preclinical tumor models [Abstract]. Proc Am Assoc Cancer Res 1989;30:623.
13. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients. A concise QL-index for use by physicians. J Chronic Dis 1981;34:585-97.
14. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs 1978;1:373-8.
15. Lee ET. Statistical methods in survival data analyses. New York: John Wiley and Sons, 1992.
16. Zar J. Biostatistical analysis. Englewood Cliffs, NJ: Prentice-Hall, 1984.
17. Glantz SA, Slinker BK. Primer of applied regression and analysis of variance. New York: McGraw-Hill, 1990.
18. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
19. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12:553-9.
20. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994;54:1431-9.
21. Katz EJ, Vick JS, Kling KM, et al. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer 1990;26:724-7.
22. Kim JH, Kim SH, Kolozsvary A, et al. Potentiation of radiation response in human carcinoma cells in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 1992;22:515-8.